Commercial development of stem cell technology: lessons from the past, strategies for the future.
This paper presents historical and contemporary survey data on the commercial development of stem cell technology from the 1990s to the present day. We describe the first wave of industrial investment in hematopoietic stem cells during the 1990s and contrast this with the more recent expansion of the sector. In particular, we explore the cell types used, diseases targeted and business models adopted by firms. We conclude, by arguing that the commercial prospects for stem cell technologies remain highly uncertain and that innovative public policies should be adopted to prevent 'market failure'.
Martin
Paul A
PA
University of Nottingham, Institute for the Study of Genetics, Biorisks and Society (IGBiS), Nottingham, UK. paul.martin@nottingham.ac.uk
Coveney
Catherine
C
Kraft
Alison
A
Brown
Nik
N
Bath
Philip
P
D018952:Antigens, CD34 / Q000276:immunology*; D016026:Bone Marrow Transplantation; D004345:Drug Industry / Q000639:trends*; D016298:Hematopoietic Cell Growth Factors / Q000378:metabolism*; D006412:Hematopoietic Stem Cells / Q000166:cytology* / Q000276:immunology; D006801:Humans
D018952:Antigens, CD34; D016298:Hematopoietic Cell Growth Factors